Antibodies: Top pre-clinical and clinical ADC programs from Pfizer

In Antibodies, Clinical Trials by charlottebLeave a Comment

#Antibodies: Do you agree that novel research concepts have the potential to transform ADC development?

Pfizer, ADC, antibodydrugconjugate, bioconjugateDr Hans-Peter Gerber, now a Executive Director of BioConjugate Discovery and Development at Pfizer gave a review of how these novel research concepts for studying ADC targets, targeting vehicles, linkers and payloads could and perhaps are impacting this industry.

Pre-clinical and clinical ADC programs

  • Differences in the mechanism of action between calicheamicin and tubulin inhibitor based ADCs
  • Preclinical development of an ADC targeting the oncofetal antigen 5T4, expressed on tumor initiating cells in a variety of solid tumors
  • Phase II/III Clinical update on CMC-544, an anti-CD22 calicheamicin conjugate developed in NHL

Follow the link below for the presentation slides delivered at the 2011 European Antibody Congress, and find out the details!

http://www.terrapinn.com/template/live/documents.aspx?e=5273&d=6889

Do you want to find out more?

Top new results of #antibody therapeutic developments from Dr Janice Reichert

How Novartis are predicting #Antibody stability

How to define acceptable changes for QA's of #antibodies

Leave a Comment

Current ye@r *